Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-059-4 | CAS number: 920-66-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 31 August 2007 - 30 March 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: OECD Guideline study under GLP conditions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,1,1,3,3,3-hexafluoropropan-2-ol
- EC Number:
- 213-059-4
- EC Name:
- 1,1,1,3,3,3-hexafluoropropan-2-ol
- Cas Number:
- 920-66-1
- Molecular formula:
- C3H2F6O
- IUPAC Name:
- 1,1,1,3,3,3-hexafluoropropan-2-ol
- Details on test material:
- - Physical state: Colorless clear liquid
- Purity: 99.9%
- Lot/batch No.: 3SMZD
- Stability under test conditions: Stable
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan (Atsugi Farm)
- Age at study initiation: 9 weeks-old
- Weight at study initiation: Male: 317-361 g, Female: 199-251 g
- Fasting period before study: none
- Housing: Males and females were housed in stainless-steel wire-meshed cages except for gestation and lactation periods. During gestation and lactation periods, females were housed in polycarbonate cages.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: one week including quarantine period
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.8-23.6°C
- Humidity (%): 49.8-61.8%
- Air changes (per hr): 6-20 times per hour
- Photoperiod (hrs dark / hrs light): 12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Dosing solutions were prepared daily before administration Using purified water as a vehicle, solution with a concentration of 30 mg/mL was prepared first. Then, the
solution was diluted with vehicle and prepared as solutions with concentrations of 1 and 6 mg/L. - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- M/F ratio per cage:1:1
- Length of cohabitation: Length of cohabitation: 14 days (maximum)
- Proof of pregnancy: Vaginal plug or sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- Male: 42 days including 14-days pre-mating period and mating period
Female: 42-52 days including 14 days pre-mating, mating and gestation periods, and days until lactation day 4. - Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 10, 60, 300 mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- Administration groups:
Control and high dose groups: 7 males and 12 females per dose
Low and mid dose groups: 12 per sex per dose
Recovery groups:
Control and high dose groups: 5 per sex per dose - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: In 14-days preliminary study, a dose of 500 mg/kg/day tested was proved to be excess because of poor general conditions for the test animals. As a consequence, the top dose in the
main study was set down to 300 mg/kg/day. The mid and low doses were set as 60 and 10 mg/kg/day, respectively.
- Rationale for selecting satellite groups: Satellite groups for recovery study were set for control and high dose groups.
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: 3 times (before and just after administration and about 3 hrs after administration) per day during administration period. Once daily during period other than administration.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations: (Males) Day 1, 8, 15. 22, 29, 36, 42 and 43. (Females) Pre-mating Day 0, 7 and 17, once a week during mating period, gestation day (GD) 0, 7, 14 and 20, and lactation day 0 and 4. (Males and females, recovery groups) Day 50 and 56.
FOOD CONSUMPTION :
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/day: Yes
HAEMATOLOGY: Yes
- Time schedule for collection of blood: (Males) Day 43; (Females) Lactation day 5; (Males and females, recovery) Day 57
- Anaesthetic used for blood collection: Yes (sodium pentobarbital)
- Animals fasted: Yes, 18-23 hrs from the day before.
- How many animals: 5 per sex per group
- Parameters checked in table 1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: the same schedule as haematology
- Animals fasted: Yes
- How many animals: 5 per sex per group
- Parameters checked in table 2 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: the day before start of administration, once a week during administration until Week-6.
- Dose groups that were examined:
- Battery of functions tested: sensory activity / grip strength / motor activity / other: reactivity to stimuli - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: No data
- Number of late resorptions: No data - Fetal examinations:
- - External examinations: Yes: all per litte
- Soft tissue examinations: No
- Skeletal examinations: No
- Head examinations: No - Statistics:
- For parametric data, homogeneity of variance was examined by Bartlett method. When the variance was equal, ANOVA was used. While variance was not equal or non-parametric data was applied, Kruskal-Wallis
method was used. When significant difference was recognized among the groups, either Dunnett method or Dunnett multiple comparison test was used. For qualitative data, Dunnett multiple comparison test,
Wilcoxon rank sum test, Fischer's exact probability, Student or Aspin-Welch's t-test were used as necessary. - Indices:
- Implantation index (%) = (Number of implantation sites/number of corpora lutea)×100
Delivery index (%) = (Number of pups delivered/number of implantation sites)×100
Live birth index (%) = (Number of live pups on day 0/number of pups delivered)×100
Viability index (%) = (Number of live pups on day 4/number of live pups on day 0)×100
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
See 7.5.1 Repeated dose toxicity oral
300 mg/kg: death (female), clinical signs (depression of central nervous system, anesthetic action)(both sexes), decrease in body weight
(both sexes), irritating changes in gastrointestinal tract.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
In offspring at 300 mg/kg, among fetuses or dead offsprings of 3 dams including the dead dam during the gestation period, generalized edema and protruding tongue were observed in 20 fetuses/offsprings and in 22 fetuses/offsprings, respectively.
In this group, increased pleural fluid was observed in 3 offsprings.
Blackish and/or dark reddish abnormal contents in the intestine were observed in 6 offsprings.
Since it is reported that ethanol similar to a monohydric alcohol (C3) of PHF affected the offspring’s intestines by embryonic exposure, this change was suspected to be test substance effects.
At 300 mg/kg, in addition to total litter loss in 3 dams including the above mentioned dystosia, the number of dead offsprings increased until 4 days after birth.
Consequently, the number of live offspring and viability index on day 4 decreased.
For these changes, the anesthetic action of the test substance was likely to work on the maternal behavior.
Moreover, although the body weight at birth was comparable to that of the control group in both sexes, the variability index and body weight on day 4 decreased.
There were no significant differences between the test substance-treated groups and control group in number of days until copulation, incidence of females without the estrous cycle, fertility index, implantation index, numbers of corpora lutea and implantation, gestation index, and number of offspring.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Table 1 Delivery and litter data in rats treated orally with 2-Propanol, 1,1,1,3,3,3-hexafluoro- the combined repeated dose and reproductive/developmental toxicity screening test
Dose level (mg/kg) | Administration period | |||
0 | 10 | 60 | 300 | |
Number of females examined | 12 | 12 | 11 | 10 |
Number of females with live pups |
12 | 12 | 11 | 9 |
Gestation index (%) a) | 100.0 | 100.0 | 100.0 | 90.0 |
Gestation length (days) | 22.3 ± 0.5 | 22.6 ± 0.5 | 22.7 ± 0.5 | 23.4 ± 0.7** |
Number of corpora lutea | 16.3 ± 2.3 | 17.5 ± 1.8 | 16.9 ± 2.8 | 17.7 ± 2.5 |
Number of implantation sites | 15.2 ± 2.0 | 16.4 ± 1.8 | 15.3 ± 3.4 | 16.2 ± 2.4 |
Implantation index (%) b) | 93.03 ± 4.60 | 93.93 ± 5.44 | 89.18 ± 9.10 | 91.78 ± 4.35 |
Delivery index (%) c) | 95.68 ± 4.75 | 92.38 ± 4.38 | 95.40 ± 6.44 | 80.64 ± 18.94 |
Number of pups delivered | 14.5 ± 2.0 | 15.2 ± 1.9 | 14.5 ± 3.4 | 13.3 ± 4.5 |
Number of live pups on day 0 | 14.5 ± 2.0 | 15.1 ± 1.9 | 14.3 ± 3.4 | 10.4 ± 4.9 |
Number of live pups on day 4 | 14.3 ± 2.1 | 14.9 ± 1.6 | 14.2 ± 3.4 | 5.2 ± 5.3** |
Live birth index (%) d) | 100.00 ± 0.00 | 99.44 ± 1.93 | 98.10 ± 3.30 | 70.20 ± 33.60** |
Viability index on day 4 (%) e) | 98.23 ± 3.28 | 99.07 ± 2.18 | 99.44 ± 1.87 | 39.71 ± 40.52** |
Sex ratio of total number of offspring at birth (M/Total) | 0.53 (92/174) | 0.51 (92/182) | 0.46 (73/160) | 0.53 (62/117) |
Sex ratio of total number of live offspring at birth (M/Total) | 0.53 (92/174) | 0.51 (92/181) | 0.45 (71/157) | 0.57 (54/94) |
Sex ratio of total number of live offspring on day 4 (M/Total) | 0.53 (91/171) | 0.51 (91/179) | 0.45 (70/156) | 0.55 (26/47) |
Sex ratio of total number of offspring at birth (M/Total, litter) | 0.531 ± 0.098 | 0.497 ± 0.124 | 0.464 ± 0.110 | 0.497 ± 0.208 |
Sex ratio of total number of live offspring at birth (M/Total, litter ) | 0.531 ± 0.098 | 0.499 ± 0.122 | 0.458 ± 0.105 | 0.577 ± 0.145 |
Sex ratio of total number of live offspring on day 4 (M/Total, litter ) | 0.533 ± 0.097 | 0.501 ± 0.123 | 0.455 ± 0.103 | 0.650 ± 0.208 |
Body weight of pups (g) | ||||
on day 0 male | 6.7 ± 0.4 | 6.9 ± 0.6 | 7.1 ± 0.7 | 6.3 ± 0.4 |
on day 0 female | 6.3 ± 0.4 | 6.5 ± 0.6 | 6.7 ± 0.9 | 5.8 ± 0.3 |
on day 4 male | 10.4 ± 0.9 | 10.7 ± 1.0 | 11.1 ± 2.2 | 7.1 ± 2.3* |
on day 4 female | 9.9 ± 1.0 | 10.2 ± 1.0 | 10.5 ± 2.2 | 7.4 ± 1.5* |
a) Gestation index (%) = (Number of females with live pups/number of pregnant females)×100
b) Implantation index (%) = (Number of implantation sites/number of corpora lutea)×100
c) Delivery index (%) = (Number of pups delivered/number of implantation sites)×100
d) Live birth index (%) = (Number of live pups on day 0/number of pups delivered)×100
e) Viability index (%) = (Number of live pups on day 4/number of live pups on day 0)×100
Values are expressed as Mean±S.D.
Significantly different from 0 mg/kg group; * p<0.05, **p<0.01
Applicant's summary and conclusion
- Conclusions:
- As for the reproductive and developmental toxicity, the NOEL and NOAEL for parental animals and offspring were judged to be 60 mg/kg/day, since prolonged estrous cycle and gestation length, decreased copulation index and delivery index in dams as well as generalized edema and protruding tongue, a change in the color of the gastrointestinal contents, decreased number of live offspring, body weight, and viability index in offspring were noted in the 300 mg/kg group.
- Executive summary:
In accordance with the OECD guideline on combined repeated dose and reproductive/developmental toxicity screening test, 2-propanol, 1,1,1,3,3,3-hexafluoro- (PHF) was studied for oral toxicity in rats at doses of 0, 10, 60, and 300 mg/kg/day.
At 300 mg/kg, the mean estrous cycle was prolonged to 6 days in 4 dams and the mean estrous cycle in this group was significantly prolonged. The copulation index was 83.3% (10/12 animals) at 300 mg/kg while other groups were all 100 % (12/12 animals). During the gestation period, none of the dams completed the delivery on day 22 of gestation and one of them showed dystosia as it delivered on day 25 of gestation. The gestation length was prolonged in this group. These changes were suspected to be caused by anesthetic action of the test substance. In numbers of corpora lutea, implantations, and offspring, although they were comparable to the control values, number of live offspring and delivery index decreased.
In offspring at 300 mg/kg, among fetuses or dead offsprings of 3 dams including the dead dam during the gestation period, generalized edema and protruding tongue were observed in 20 fetuses/offsprings and in 22 fetuses/offsprings, respectively. In this group, increased pleural fluid was observed in 3 offsprings. Blackish and/or dark reddish abnormal contents in the intestine were observed in 6 offsprings. Since it is reported that ethanol similar to a monohydric alcohol (C3) of PHF affected the offspring’s intestines by embryonic exposure, this change was suspected to be test substance effects. At 300 mg/kg, in addition to total litter loss in 3 dams including the above mentioned dystosia, the number of dead offsprings increased until 4 days after birth. Consequently, the number of live offspring and viability index on day 4 decreased. For these changes, the anesthetic action of the test substance was likely to work on the maternal behavior. Moreover, although the body weight at birth was comparable to that of the control group in both sexes, the variability index and body weight on day 4 decreased.
There were no significant differences between the test substance-treated groups and control group in number of days until copulation, incidence of females without the estrous cycle, fertility index, implantation index, numbers of corpora lutea and implantation, gestation index, and number of offspring.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.